Subscribe to Newsletter
Diagnostics Genetics and epigenetics, Hematology

Genomic profiling from initial assessment to detection of measurable residual disease (MRD): how NGS can rapidly deliver key insights for myeloid neoplasms

sponsored by Thermo Fisher Scientific

Register here

July 27, 2022 - 08:00AM PDT

Myeloid neoplasms are a heterogeneous group of blood and bone marrow-based disorders, primarily including myelodysplastic syndromes (MDS), myeloproliferative neoplasms (MPN), and acute myeloid leukemia (AML). 

Comprehensive molecular analysis is critical for characterizing myeloid samples, understanding disease pathology, detecting residual disease mutations, and potentially informing risk-adapted therapeutic strategies. 

Next-generation sequencing (NGS) is a transformative molecular testing technology that rapidly and simultaneously analyzes multiple genetic biomarkers, providing a comprehensive genomic profile from a single test. 

During this presentation, Dr. Bevan Tandon of Pathline Labs will review ongoing studies in his laboratory using the Oncomine Myeloid Assay GX, an NGS-based test capable of delivering results in just 1-2 days. 

He will also share his experience with the upcoming Oncomine Myeloid MRD Assay (RUO), a highly sensitive NGS test for measurable residual disease (MRD) assesment that can identify mutations occurring at very low frequencies. Dr. Tandon will share recent analytical data from his team and offer his perspective on the value of NGS in hematopathology studies. 

Webinar Learning Objectives:

  • The latest advancements in NGS for molecular testing of myeloid neoplasms
  • How genomic profiling can provide deep insight for the assessment myeloid samples
  • How NGS can benefit myeloid MRD analysis

Register here

Visit our Webinar Hub

Receive content, products, events as well as relevant industry updates from The Pathologist and its sponsors.
Stay up to date with our other newsletters and sponsors information, tailored specifically to the fields you are interested in

When you click “Subscribe” we will email you a link, which you must click to verify the email address above and activate your subscription. If you do not receive this email, please contact us at [email protected].
If you wish to unsubscribe, you can update your preferences at any point.

Related Application Notes
Evaluation of cell-free fetal DNA to determine fetal RhD status

| Contributed by Revvity

Preventing Bias in scRNAseq Performed on Solid Tumors

| Contributed by Revvity

Enabling Efficient, Cost-effective Sequencing of the Human Whole Exome

| Contributed by Revvity

Related Product Profile
Diagnostics Genetics and epigenetics
QIAseq® Pan Cancer Multimodal cuts user interventions by 50%

| Contributed by QIAGEN

Most Popular
Register to The Pathologist

Register to access our FREE online portfolio, request the magazine in print and manage your preferences.

You will benefit from:
  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Pathologist magazine